| Drug 1 | |
| Generic/Working Name | Crizotinib |
| Trade Name | Xalkori |
| Company Name | Pfizer Inc. |
| Drug Type | Small molecule |
| Drug Class | ALK inhibitor |
| Dose | 250 milligrams (mg) per flat dose |
| Route | Oral (p.o.) |
| Schedule of Administration | Dose level –1: 250 mg b.i.d. as monotherapy for 3 weeks (lead‐in) then in combination with pembrolizumab |
| Drug 2 | |
| Generic/Working Name | Pembrolizumab |
| Trade Name | Keytruda |
| Company Name | Merck Sharp & Dohme |
| Drug Type | Monoclonal antibody |
| Drug Class | Programmed death receptor‐1 (PD‐1 blocking antibody) |
| Dose | 200 milligrams (mg) per flat dose |
| Route | IV |
| Schedule of Administration | Dose level –1: 200 mg every 3 weeks after crizotinib monotherapy lead‐in period |
| Abbreviations: ALK, anaplastic lymphoma kinase; b.i.d., twice a day; p.o., by mouth. | |